Wenting Guo

Dr. Wenting Guo


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2022 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
WGWenting Guo
Wenting Guo
JXJiali Xu
Jiali Xu
LMLinqing Ma
Linqing Ma
JMJin Ma
Jin Ma
SLSijie Li
Sijie Li
Xunming JiXunming Ji
Xunming Ji
Objective: This study aimed to explore the effect of different administration routes of a low dose of tirofiban on acute ischemic stroke (AIS) patients with successful recanalization after endovascular treatment (EVT).Methods: This is a cohort study that retrospectively analyzed data of patients with AIS who underwent EVT and achieved successful recanalization from a prospective registry. Eligible patients were divided into three groups according to their use of tirofiban. Propensity score matching (PSM) was used to balance baseline bias. Safety outcomes included any intracranial hemorrhage (ICH) and symptomatic ICH (sICH). Efficacy outcomes included arterial reocclusion, in‐hospital mortality, 3‐month mortality, and 3‐month functional outcomes.Results: We included 821 patients with 306 in the no tirofiban group, 202 in the IA + IV tirofiban group, and 313 in the IV tirofiban group. After PSM, each group included 101 patients with balanced baseline characteristics. There was no difference between the IV tirofiban group and the no tirofiban group in terms of safety and efficacy outcomes (all p > 0.05). Compared with no tirofiban, IA + IV tirofiban group did not increase ICH (30.7% vs. 37.6%, p > 0.05) and sICH (6.9% vs. 17.8%, p > 0.05) whereas reduced 3‐month mortality (14.3% vs. 28.7%, p < 0.05) and improved 3‐month modified Rankin Scale (median 3 vs. 4, p < 0.05).Conclusions: A low dose of tirofiban, regardless of their administration routes, was safe for AIS patients who achieved successful recanalization with EVT, whereas only IA + IV tirofiban improved clinical outcomes.

10 February 2023 in Environmental Science & Technology
Verified
Journal Article
Closed access
HYHuihua Yang
Huihua Yang
YZYuming Zheng
Yuming Zheng
XLXuefeng Lai
Xuefeng Lai
LZLei Zhao
Lei Zhao
LLLin-lin Liu
Lin-lin Liu
XZXiaomin Zhang
Xiaomin Zhang

1 June 2023 in Hypertension
Verified
Journal Article
Closed access
WGWenting Guo
Wenting Guo
WZWenbo Zhao
Wenbo Zhao
DLDong Li
Dong Li
HJHaiying Jia
Haiying Jia
CRChanghong Ren
Changhong Ren
Xunming JiXunming Ji
Xunming Ji
Background: Exploratory studies have shown that remote ischemic conditioning (RIC) has the potential to lower blood pressure (BP). We investigated whether chronic RIC reduces BP for hypertension. Methods: This is a multicenter, randomized, double-blind, parallel-controlled trial. Patients with an office BP of 130/80 to 160/100 mm Hg and a 24-hour average BP ≥125/75 mm Hg not on antihypertensive medications were recruited. After a 1-week compliance screening phase, they were randomly assigned in a 1:1 ratio to receive RIC or sham RIC twice daily for 4 weeks. The primary efficacy outcome was the change in 24-hour average systolic BP from baseline to 4 weeks. Safety events were assessed over the study period. Results: Ninety-five participants were randomly allocated to the RIC (n=49) and sham RIC (n=46) groups. In the intention-to-treat analysis, the reduction in 24-hour average systolic BP was greater in the RIC group than the sham RIC group (−4.6±9.5 versus −0.9±6.8 mm Hg; baseline-adjusted between-group mean difference: −3.6 mm Hg [95% CI, −6.9 to −0.3 mm Hg]; adjusted P =0.035). The per-protocol analysis showed that 24-hour average systolic BP reduced −5.9±8.6 mm Hg in the RIC group and −0.7±6.7 mm Hg in the sham RIC group (baseline-adjusted between-group mean difference: −5.2 mm Hg [95% CI, −8.5 to −1.9 mm Hg]; adjusted P =0.002). No major adverse events were reported in both groups. Conclusions: RIC is safe in patients with mild hypertension and may lower BP in the absence of antihypertensive medications. However, the effects of RIC on clinical outcomes in these patients require further investigation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04915313.

12 March 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
MZMengke Zhang
Mengke Zhang
RCRuiwen Che
Ruiwen Che
JXJiali Xu
Jiali Xu
WGWenting Guo
Wenting Guo
XCXi Chen
Xi Chen
Xunming JiXunming Ji
Xunming Ji
Aims: With the progress of thrombectomy technology, the vascular recanalization rate of patients with stroke has been continuously improved, but the proportion of futile recanalization (FR) is still quite a few. The long‐term prognosis and survival of patients with FR and its influencing factors remain unclear.Methods: Consecutive patients who received endovascular treatment (EVT) for ischemic stroke were enrolled between 2013 and 2021 from a single‐center prospectively registry study. We evaluated the long‐term outcome of these patients by Kaplan–Meier survival analysis, and the multivariable logistic regression curve was performed to analyze influencing factors.Results: Among 458 patients with FR, 56.4% of patients survived at 1 year, and 50.4% at 2 years. In the multivariate regression analysis, age, premorbid modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), posterior circulation infarct, general anesthesia, symptomatic intracerebral hemorrhage (sICH), and decompressive craniectomy were found to be related to unfavorable outcomes in long‐term. Age, premorbid mRS, NIHSS, general anesthesia, and sICH were predictors of long‐term mortality.Conclusions: Futile recanalization accounts for a large proportion of stroke patients after thrombectomy. This study on the long‐term prognosis of such patients is beneficial to the formulation of treatment plans and the prediction of therapeutic effects.

24 May 2023 in The Neurologist
Verified
Journal Article
Closed access
WYWantong Yu
Wantong Yu
CRChanghong Ren
Changhong Ren
JDJubao Du
Jubao Du
WZWenbo Zhao
Wenbo Zhao
WGWenting Guo
Wenting Guo
Xunming JiXunming Ji
Xunming Ji
Background: Remote ischemic conditioning (RIC) has shown an impressive neuroprotective effect on acute ischemic stroke (AIS) in animal experiments. But whether chronic RIC improves long-term functional outcomes remains unclear. Materials and Methods: We performed a non-randomized controlled trial. Eligible patients (aged 18 –80 y) with hemiplegia caused by AIS were allocated to the RIC group and the control group. All participants received normal protocol rehabilitation therapy. Patients in the RIC group underwent RIC twice daily for 90 days. The outcome included the 90-day Fugl-Meyer Assessment (FMA) scores and modified Rankin’s scale (mRS) scores, as well as changes in angiogenesis-related factors in serum from baseline to 90 days. Results: Twenty-seven patients were included in the analysis (13 in the RIC group and 14 in the control group). There was no significant difference in 90-day total FMA scores between the two groups. Lower limb FMA scores at day 90 were significantly higher in the RIC group (32.8±8.7 vs. 24.8±5.4, adjusted P=0.042). The proportion of favorable outcome (mRS<2) was higher in the RIC group than that in the control group, but no significant difference was detected (8 [61.5%] vs. 7 [50%], P=0.705). A significant increase has been found in the level of epidermal growth factor (EGF) in serum (9.4 [1.1 to 25.7] vs. −8.7 [−15.1 to 4.7], P=0.036) after chronic RIC procedure. Conclusion: This study investigated the role that RIC plays in AIS recovery, especially in motor function. RIC may have beneficial effects on lower limbs recovery by enhancing the EGF level. The effect of RIC on motor recovery should be further validated in future studies.

22 February 2022 in Behavioural Brain Research
Verified
Journal Article
Closed access
HYHui Yao
Hui Yao
WGWenting Guo
Wenting Guo
LSLonglong Suo
Longlong Suo
Guoliang LiGuoliang Li
Guoliang Li
YWYunsheng Wang
Yunsheng Wang
RDRuntao Ding
Runtao Ding